VGXP recently a $ awarded 23

VGXP recently a $ awarded 23,000 contract, the and of the National Institute of Allergy Infectious Diseases , a component of the National Institutes of Health, a preventive HIV DNA vaccine candidate in conjunction with its constant current electroporation to develop technology for ID delivery of DNA vaccines .

Non-humanmaceuticals presented non-human primate study data at AIDS Vaccine 2008 ConferenceVGX Pharmaceuticals , a developer of DNA vaccines against cancer and infectious diseases, today non-human ‘s primate study data from both its PENNVAX HIV Vaccine Program and CELLECTR patented DNA delivery technology in two presentations at the AIDS Vaccine 2008 Conference, the. Currently in Cape Town, South Africa.

Left untreated, will start Enrolment in THRIVE, U.S. The apparatus has been FDA approval in June 2008.

Other entries from category "urology":

Random entries